Biogen is hustling a schizophrenia drug into PhIIb after Pfizer lets it go in $590M CNS fire sale
Pfizer’s $PFE decision to beat a retreat from its pipeline of neurosciences drugs has triggered its first asset sale.
Biogen $BIIB is stepping up with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
